Tactical applications of fluorine in drug design and development

Fluorine in Heterocyclic Chemistry: Volume 1: 5-Membered Heterocycles and Macrocycles

Volumn , Issue , 2014, Pages 1-54

  Meanwell, Nicholas A ^a   Eastman, Kyle J ^a   Gillis, Eric P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Fluorine and basicity; Fluorine and conformation; Fluorine and hydrogen bonding; Fluorine and membrane permeability; Fluorine and metabolic stability; Gauche interaction; Positron emitting tomography imaging

Indexed keywords

AMINES; HYDROGEN BONDS; METABOLISM; PHYSICOCHEMICAL PROPERTIES; POSITRONS; TOMOGRAPHY;

BIOLOGICALLY ACTIVE MOLECULES; DESIGN AND OPTIMIZATION; ELECTRONWITHDRAWING; EMERGING APPLICATIONS; GAUCHE INTERACTION; MEMBRANE PERMEABILITY; METABOLIC STABILITY; TOMOGRAPHY IMAGING;

CONFORMATIONS;

EID: 84947203195     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-04346-3_1     Document Type: Chapter

References (201)

1. Vulpetti A, Hommel U, Landrum G, Lewis R, Dalvit C (2009) Design and NMR-based screening of LEF, a library of chemical fragments with different local environments of fluorine. J Am Chem Soc 131:12949–12959
2. Jordan JB, Poppe L, Xia X, Cheng AC, Sun Y, Michelsen K, Eastwood H, Schnier PD, Nixey T, Zhong W (2012) Fragment based drug discovery: practical implementation based on 19 F NMR spectroscopy. J Med Chem 55:678–687
3. Vulpetti A, Dalvit C (2012) Fluorine local environments: from screening to drug design. Drug Discov Today 17:890–897
4. Harper DB, O’Hagan D, Murphy CD (2003) The handbook of environmental chemistry, vol 3 Part P. Springer, Berlin/Heidelberg, pp 141–169
5. Bowen HJM (1966) Trace elements in biochemistry. Academic, London
6. Sharpe AG (1967) In: Gutmann V (ed) Halogen chemistry, vol 1. Academic, New York, p 12
7. Neidleman SL, Geigert J (1986) Biohalogenation: principles, basic roles and applications. Ellis Horwood Ltd, Chichester
8. Vaillancourt F, Yeh E, Vosburg DA, Garneau-Tsodikova S, Walsh CT (2006) Nature’s inventory of halogen catalysts: oxidative strategies predominate. Chem Rev 106:3364–3378
9. O’Hagan D (2006) Recent developments on the fluorinase of streptomyces cattleya. J Fluor Chem 127:1479–1483
10. Zhu X, Robinson DA, McEwan AR, O’Hagan D, Naismith JH (2007) Mechanism of enzymatic fluorination in Streptomyces cattleya. J Am Chem Soc 139:14597–14604
11. Wagner C, El Omari M, König GM (2009) Biohalogenation: nature’s way to synthesize halogenated metabolites. J Nat Prod 72:540–553
12. Meyer M, O’Hagan D (1992) Rare fluorinated natural products. Chem Br 28:785
13. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J (1957) Fluorinated pyrimidines, a new class of tumourinhibitory compounds. Nature 179:663–666
14. Bégué J-P, Bonnet-Delpon D (2008) Bioorganic and medicinal chemistry of fluorine. Wiley, Hoboken
15. Böhm H-J, Banner D, Bendels S, Kansy M, Kuhn B, Müller K, Obst-Sander U, Stahl M (2004) Fluorine in medicinal chemistry. ChemBioChem 5:637–643
16. Müller K, Faeh C, Diederich F (2007) Fluorine in pharmaceuticals: looking beyond intuition. Science 317:1881–1886
17. Hagmann WK (2008) The many roles for fluorine in medicinal chemistry. J Med Chem 51:4359–4369
18. Purser S, Moore PR, Swallow S, Gouverneur V (2008) Fluorine in medicinal chemistry. Chem Soc Rev 37:320–330
19. Shah P, Westwell AD (2007) The role of fluorine in medicinal chemistry. J Enzym Inhib Med Chem 22:527–540
20. O’Hagan D (2008) Understanding organofluorine chemistry: an introduction to the C-F bond. Chem Soc Rev 37:308–319
21. Hunter L (2010) The C-F bond as a conformational tool in organic and biological chemistry. Belistein J Org Chem 6. doi:103762/bjoc.6.38
22. Zimmer LE, Sparr C, Gilmour R (2011) Fluorine conformational effects in organocatalysis: an emerging strategy for molecular design. Angew Chem Int Ed 50:11860–11871
23. Buissonneaud DY, van Mourik T, O’Hagan D (2010) A DFT study on the origin of the fluorine gauche effect in substituted fluoroethanes. Tetrahedron 66:2196–2202
24. O’Hagan D (2012) Organofluorine chemistry: synthesis and conformation of vicinal fluoromethylene motifs. J Org Chem 77:3689–3699
25. Wu D, Tian A, Sun H (1998) Conformational properties of 1,3-difluoropropane. J Chem Phys A 102:9901–9905
26. Tavasli M, O’Hagan D, Pearson C, Petty MC (2002) The fluorine gauche effect. Langmuir isotherms report the relative conformational stability of (±)- erythro - and (±)- threo -9,10-difluorostearic acids. Chem Commun 1226–1227
27. Hunter L, Kirsch P, Slawin AMZ, O’Hagan D (2009) Synthesis and structure of stereoisomeric multivicinal hexafluoroalkanes. Angew Chem Int Ed 48:5457–5460
28. Banks JW, Batsanov AS, Howard JAK, O’Hagan D, Rzepa H, Martin-Santamaria S (1999) The preferred conformation of α-fluoroamides. J Chem Soc Perkin 2:2409–2411
29. Briggs CRS, O’Hagan D, Howard JAK, Yulfi DS (2003) The C-F bond as a tool in the conformational control of amides. J Fluor Chem 119:9–13
30. Dalvit D, Vulpetti A (2012) Intermolecular and intramolecular hydrogen bonds involving fluorine atoms: implications for recognition, selectivity, and chemical properties. ChemMedChem 7:262–272
31. Schϋler M, O’Hagan D, Slawin AMZ (2005) The vicinal F-C-C-F moiety as a tool for influencing peptide conformation. Chem Commun 4324–4326
32. O’Hagan D, Rzepa HS, Schϋler M, Slawin AMZ (2006) The vicinal difluoro motif: the synthesis and conformation of erythro - and threo -diastereomers of 1,2-difluorodiphenylethanes, 2,3-difluorosuccinic acids and their derivatives. Beilstein J Org Chem. doi: 10.1186/1860-5397-2-19
33. Winkler M, Moraux T, Khairy HA, Scott RH, Slawin AMZ, O’Hagan D (2009) Synthesis and vanilloid receptor (TRPV1) activity of the enantiomers of α-fluorinated capsaicin. ChemBioChem 10:823–828
34. Peddie V, Butcher RJ, Robinson WT, Wilce MCJ, Traore DAK, Abell AD (2012) Synthesis and conformation of fluorinated β-peptidic compounds. Chem Eur J 18:6655–6662
35. O’Hagan D, Bilton C, Howard JAK, Knight L, Tozer DJ (2001) The preferred conformation of N-β-fluoroethylamides: observation of the fluorine amide gauche effect. J Chem Soc Perkin Trans 2:605–607
36. O’Hagan D, Rzepa HS (1997) Some influences of fluorine in bioorganic chemistry. Chem Commun 645–652
37. Holmgren SK, Taylor KM, Bretscher LE, Raines RT (1998) Code for collagen’s stability deciphered. Nature 392:666–667
38. Bretscher LE, Jenkins CL, Taylor KM, DeRider ML, Raines RT (2001) Conformational stability of collagen relies on a stereoelectronic effect. J Am Chem Soc 123:777–778
39. Hodges JA, Raines RT (2003) Stereoelectronic effects on collagen stability: the dichotomy of 4-fluoroproline diastereomers. J Am Chem Soc 125:9262–9263
40. Doi M, Nishi Y, Uchiyama S, Nisiuchi Y, Nakazawa T, Ohkubo T, Kobayasji Y (2003) Characterization of collagen model peptides containing 4-fluoroproline: (4(S)-fluoroproline-Pro-Gly)10 forms a triple helix, but (4(R)-fluoroproline-Pro-Gly)10 does not. J Am Chem Soc 125:9922–9923
41. Hodges JA, Raines RT (2005) Stereoelectronic and steric effects in the collagen triple helix: toward a code for strand association. J Am Chem Soc 127:15923–15932
42. Shoulders MD, Kamer KJ, Raines RT (2009) Origin of the stability conferred upon collagen by fluorination. Bioorg Med Chem Lett 19:3859–3862
43. Doi M, Nishi Y, Kiritoshi N, Iwata T, Nago M, Nakano H, Uchiyama S, Nakazawa T, Wakamiya T, Kbayashi Y (2002) Simple and efficient syntheses of Boc- and Fmocprotected 4(R)- and 4(S)-fluoroproline solely from 4(R)-hydroxyproline. Tetrahedron 58:8453–8459
44. DeRider ML, Wilkins SJ, Waddell MJ, Bretscher LE, Weinhold F, Raines RT, Markley JL (2002) Collagen stability: insights from NMR spectroscopic and hybrid density functional computational investigations of the effect of electronegative substituents on prolylring conformations. J Am Chem Soc 124:2497–2505
45. Park S, Radmer RJ, Klein TE, Pande VS (2005) A new set of molecular mechanics parameters for hydroxyproline and its use in molecular dynamics simulations of collagen-like peptides. J Comput Chem 26:1612–1616
46. Hodges JA, Raines RT (2006) Energetics of an n → π* interaction that impacts protein structure. Org Lett 8:4695–4697
47. Hinderaker MP, Raines RT (2003) An electronic effect on protein structure. Protein Sci 12:1188–1194
48. Raines RT (2006) 2005 Emil Thomas Kaiser Award. Protein Sci 15:1219–1225
49. Improta R, Mele F, Crescenzi O, Benzi C, Barone V (2002) Understanding the role of stereoelectronic effects in determining collagen stability: a quantum mechanical/molecular mechanical study of (proline-proline-glycine) n polypeptides. J Am Chem Soc 124:7857–7865
50. Kim W, Hardcastle KL, Conticello VP (2006) Fluoroproline flip-flop: regiochemical reversal of a stereoelectronic effect on peptide and protein structures. Angew Chem Int Ed 45:8141–8814
51. Kitamoto T, Ozawa T, Abe M, Marubayashi S, Yamazaki T (2008) Incorporation of fluoroprolines to proctolin: study on the effect of a fluorine atom towards peptidic conformation. J Fluor Chem 129:286–293
52. Briggs CRS, Allen MJ, O’Hagan D, Tozer DJ, Slawin AMZ, Goeta AE, Howard JAK (2004) The observation of a large gauche preference when 2-fluoroethylamine and 2-fluoroethanol become protonated. Org Biomol Chem 2:732–740
53. Lankin DC, Chandrakumar NS, Rao SN, Spangler DP, Snyder JP (1993) Protonated 3- fluoropiperidines: an unusual fluoro directing effect and a test for quantitative theories of solvation. J Am Chem Soc 115:3356–3357
54. Snyder JP, Chandrakumar NS, Sato H, Lankin DC (2000) The unexpected diaxial orientation of cis-3, 5-difluoropiperidine in water: a potent CF – NH charge-dipole effect. J Am Chem Soc 122:544–545
55. Sun A, Lankin DC, Hardcastle K, Snyder JP (2005) 3-Fluoropiperidines and N-methyl-3-fluoropiperidinium salts: the persistence of axial fluorine. Chem Eur J 11:1579–1591
56. Gerig JT, McLeod RS (1973) Conformation of cis - and trans -4-fluoro-L-proline in aqueous solution. J Am Chem Soc 95:5725–5729
57. Deniau G, Slawin AMZ, Lebl T, Chorki F, Issberner JP, van Mourik T, Heygate JM, Lambert JJ, Etherington L-A, Sillar KT, O’Hagan D (2007) Synthesis, conformation and biological evaluation of the enantiomers of 3-fluoro-γ-aminobutyric acid ((r)- and (s)-3F-GABA): an analogue of the neurotransmitter GABA. ChemBioChem 8:2265–2274
58. Clift MD, Ji H, Deniau GP, O’Hagan D, Silverman RB (2007) Enantiomers of 4-amino- 3-fluorobutanoic acid as substrates for γ-aminobutyric acid aminotransferase: conformational probes for GABA binding. Biochemistry 46:13819–13828
59. Yamamoto I, Deniau GP, Gavande N, Chebib M, Johnston GAR, O’Hagan D (2011) Agonist responses of (r)- and (s)-3-fluoro-γ-aminobutyric acids suggest an enantiomeric fold for GABA binding to GABAC receptors. Chem Commun 47:7956–7958
60. Chia PW, Livesey MR, Slawin AMZ, van Mourik T, Wyllie DJA, O’Hagan D (2012) 3-Fluoro-N-methyl-D-asaprtic acid (3F-NMDA) stereoisomers as conformational probes for exploring agonist binding at NMDA receptors. Chem Eur J 18:8813–8819
61. Gooseman NEJ, O’Hagan D, Slawin AMZ, Teale AM, Tozer DJ, Young RJ (2006) The intramolecular β-fluorine … ammonium interaction in 4- and 8-membered rings. Chem Commun 3190–3192
62. Campbell NH, Smith DL, Reszka AP, Neidle S, O’hagan D (2011) Fluorine in medicinal chemistry: β-fluorination of peripheral pyrrolidine attached to acridine ligands affects their interactions with G-quadruplex DNA. Org Biomol Chem 9:1328–1331
63. Abraham RJ, Chambers EJ, Thomas AW (1994) Conformational analysis. Part An NMR and theoretical investigation of the gauche effect in fluoroethanols. J Chem Soc Perkin Trans 2:949–955
64. Abraham RJ, Smith TAD, Thomas AW (1996) Conformational analysis. Part OH-F hydrogen bonding and the conformation of trans-2-fluorocyclohexanol. J Chem Soc Perkin Trans 2:1949–1955
65. Fried J, Sabo EF (1954) 9α-Fluoro derivatives of cortisone and hydrocortisone. J Am Chem Soc 76:1455–1456
66. Fried J (1955) Biological effects of 9 α-fluorohydrocortisone and related halogenated steroids in animals. Ann N Y Acad Sci 61:573–581
67. O’Hagan D (2010) Fluorine in health care: organofluorine-containing blockbuster drugs. J Fluor Chem 131:1071–1081
68. Mock W, Zhang JZ (1990) Concerning the relative acidities of simple alcohols. Tetrahedron Lett 31:5687–5688
69. Weeks CM, Duax WL, Wolff ME (1973) A comparison of the structure of six corticosteroids. J Am Chem Soc 95:2865–2868
70. Wolff ME, Baxter JD, Kollman PA, Lee DL, Kuntz ID, Bloom E, Matulich DT, Morris J (1978) Nature of steroid-glucocorticoid receptor interactions: thermodynamic analysis of the binding reaction. Biochemistry 17:3201–3208
71. Myers AG, Barbay JK, Zhong B (2001) Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors. J Am Chem Soc 123:7207–7219
72. Leroux F, Jeschke P, Schlosser M (2005) α-Fluorinated ethers, thioethers, and amines: anomerically biased species. Chem Rev 105:827–856
73. Massa MA, Spangler DP, Durley RC, Hickory BS, Connolly DT, Witherbee BJ, Smith ME, Sikorski JA (2001) Novel heteroaryl replacements of aromatic 3-tetrafluoroethoxy substituents in trifluoro-3-(tertiaryamino)-2-propanols as potent inhibitors of cholesterol ester transfer protein. Bioorg Med Chem Lett 11:1625–1628
74. Horne DB, Bartberger MD, Kaller MR, Monenschein H, Zhong W, Hitchcock SA (2009) Synthesis and conformational analysis of α, α-difluoroalkyl heteroaryl ethers. Tetrahedron Lett 50:5452–5455
75. Hehre WJ, Radom L, Pople JA (1972) Molecular orbital theory of the electronic structure of organic compounds. XII. Conformations, stabilities, and charge distributions in monosubstituted benzenes. J Am Chem Soc 94:1496–1504
76. Anderson GM III, Kollman PA, Domelsmith LN, Houk KN (1979) Methoxy group nonplanarity in o -dimethoxybenzenes. Simple predictive models for conformations and rotational barriers in alkoxyaromatics. J Am Chem Soc 101:2344–2352
77. Hummel W, Huml K, Bürgi H-B (1988) Conformational fl exibility of the methoxyphenyl group studies by statistical analysis of crystal structure data. Helv Chim Acta 71:1291–1302
78. Brameld KA, Kuhn B, Reuter DC, Stahl M (2008) Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis. J Chem Inf Model 48:1–24
79. Johnson F (1968) Allylic strain in six-membered rings. Chem Rev 68:375–413
80. Klocker J, Karpfen A, Wolschann P (2003) On the structure and torsional potential of trifluoromethoxybenzene: an ab initio and density functional study. Chem Phys Lett 367:566–575
81. Graton J, Wang Z, Brossard A-M, Monteiro DG, Questel J-YL, Linclau B (2012) An unexpected and signifi cantly lower hydrogen-bond-donating capacity of fluorohydrins compared to nonfluorinated alcohols. Angew Chem Int Ed 51:6176–6180
82. Meanwell N (2011) Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol 24:1420–1456
83. Peters JE, Schnider P, Mattei P, Kansy M (2009) Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 4:680–686
84. Azzaoui K, Hamon J, Faller B, Whitebread S, Jacoby E, Bender A, Jenkins JL, Urban L (2007) Modeling promiscuity based on in vitro safety pharmacology profi ling data. ChemMedChem 2:874–880
85. Jamieson C, Moir EM, Rankovic Z, Wishart G (2006) Medicinal chemistry of hERG optimizations: highlights and hang-ups. J Med Chem 49:5029–5046
86. Fischer H, Kansy M, Bur D (2000) CAFCA: a novel tool for the calculation of amphiphilic properties of charged drug molecules. Chimia 54:640–645
87. Clark J, Perrin DD (1964) Prediction of the strengths of organic bases. Q Rev Chem Soc 18:295–320
88. Morgenthaler M, Schweizer E, Hoffmann-Röder A, Benini F, Martin RE, Jaeschke G, Wagner B, Fischer H, Bendels S, Zimmerli D, Scheider J, Diederich F, Kansy M, Müller K (2007) Predicting and tuning physicochemical properties in lead optimization: amine basicities. ChemMedChem 2:1100–1115
89. Bruice PY (1984) Relative reactivity of amines and oxyanions toward proton abstraction from nitroethane. Electrostatic effects and the reactivity-selectivity principle. J Am Chem Soc 106:5959–5964
90. Trepka RD, Harrington JK, Belisle JW (1974) Acidities and partition coefficients of fluoromethanesulfonamides. J Org Chem 39:1094–1098
91. Dean JA (1999) Lange’s handbook of chemistry, 15th edn. McGraw-Hill, New York
92. Hansch C, Leo A, Taft RW (1991) A survey of Hammett substituent constants and resonance field parameters. Chem Rev 91:165c–195c
93. Taagepera M, Summerhays KD, Hehre WJ, Topsom RD, Pross A, Radom L, Taft RW (1981) Analysis of the acidities of 3- and 4-substituted pyridinium and anilinium ions. J Org Chem 46:891–903
94. Schlosser M (1998) Parametrization of substituents: effects of fluorine and other heteroatoms on OH, NH, and CH acidities. Angew Chem Int Ed 110:1496–1513
95. Olsen J, Seiler P, Wagner B, Fischer H, Tschopp T, Obst-Sander U, Banner DW, Kansy M, Muller K, Diederich F (2004) A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C-F CN interactions. Org Biomol Chem 2:1339–1352
96. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CG, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O’Rahilly S, Palmer CAN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W (2006) International Union of Pharmacology. LXI. Peroxisome proliferatoractivated receptors. Pharmacol Rev 58:726–741
97. Ciocoiu CC, Ravna AW, Sylte I, Rustan AC, Hansen TV (2011) Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516. Bio org Med Chem 19:6982–6988
98. Ishikawa M, Hashimoto Y (2011) Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. J Med Chem 54:1539–1554
99. Black WC, Bayly CI, Davis DE, Desmarais S, Falgueyret J-P, Léger S, Li CS, Massé F, McKay DJ, Palmer JT, Percival MD, Robichaud J, Tsou N, Zamboni R (2005) Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K. Bioorg Med Chem Lett 15:4741–4744
100. Herrero S, Suárez-Gea ML, Suárez-Gea ML, González-Muñiz R, García-López MT, Herranz R, Ballaz S, Barber A, Fortuño A, Del Río J (1997) Pseudopeptide CCK-4 analogues incorporating the Ψ[CH(CN)NH peptide bond surrogate. Bio org Med Chem Lett 855–860 101.
101. Kirsch P (2004) Modern fluoroorganic chemistry, synthesis, reactivity applications. Wiley-VCH, Weinheim 102.
102. Wipf P, Mo T, Geib SJ, Caridha D, Dow GS, Gerena L, Roncal N, Milner EE (2009) Synthesis and biological evaluation of the first pentafluorosulfanyl analogs of mefloquine. Org Biomol Chem 7:4163–4165
103. Welch JT, Lim DS (2007) The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem 15:6659–6666
104. Altomonte S, Zanda M (2012) Synthetic chemistry and biological activity of pentafluorosulphanyl (SF5) organic molecules. J Fluor Chem 143:57–93
105. Gujjar R, El Mazouni F, White KL, White J, Creason S, Shackleford DM, Deng X, Charman WN, Bathurst I, Burrows J, Floyd DM, Matthews D, Buckner FS, Charman SA, Phillips MA, Rathod PK (2011) Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem 54:3935–3949
106. Smith DH, Waterbeemd H, Walker DK (2001) Pharmacokinetics and metabolism in drug design, methods and principles in medicinal chemistry, vol 13. Wiley-VCH, Weinheim
107. Barnette WE (1984) The synthesis and biology of fluorinated prostacyclins. CRC Crit Rev Biochem 15:201–235
108. Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz EJ, Davies HR Jr (1997) In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 283:157–163
109. Clader JW (2004) The discovery of ezetimibe: a view from outside the receptor. J Med Chem 47:1–9
110. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn EG, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang AW, Isaakson PC (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1 H -pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 40:1347–1365
111. Rosenblum SB, Huynh T, Afonso A, Davis HR Jr, Yumibe N, Clader JW, Burnett DA (1998) Discovery of 1-(4-fluorophenyl)-(3r)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4s)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem 41:973–980
112. St Jean Jr DJ, Fotsch C (2012) Mitigating heterocycle metabolism in drug discovery. J Med Chem 55:6002–6020
113. Wan Z-K, Chenail E, Xiang J, Li H-Q, Ipek M, Bard J, Svenson K, Mansour TS, Xu X, Suri V, Hahm S, Xing Y, Johnson CE, Li X, Qadri A, Panza D, Perreault M, Tobin JF, Saiah E (2009) Effi cacious 11β-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model. J Med Chem 52:5449–5461
114. Pierson PD, Fettes A, Freichel C, Gatti-McArthur S, Hertel C, Huwyler J, Mohr P, Nakagawa T, Nettekoven M, Plancher JM, Raab S, Richter H, Roche O, Rodríguez Sarmiento RM, Schmitt M, Schuler F, Takahashi T, Taylor S, Ullmer C, Wiegand R (2009) 5-Hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity. J Med Chem 52:3855–3868
115. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A 91:12013–12017
116. Park BK, Kitteringham NR, O’Neill PM (2001) Metabolism of fluorine-containing drugs. Annu Rev Pharmacol Toxicol 41:443–470
117. Koerts J, Soffers AE, Vervoort J, De Jager A, Rietjens IM (1998) Occurrence of the NIH shift upon the cytochrome P450-catalyzed in vivo and in vitro aromatic ring hydroxylation of fluorobenzenes. Chem Res Toxicol 11:503–512
118. Dear GJ, Ismail IM, Mutch PJ, Plumb RS, Davies LS (2000) Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in rabbit, mouse and human: identification of fluorine NIH shift metabolites using NMR and tandem MS. Xenobiotica 30:407–426
119. Boguslavsky V, Bebecchi M, Morris AJ, Jhon DY, Rhee SG, McLaughlin S (1994) Effect of monolayer surface pressure on the activities of phosphoinositide-specifi c phospholipase C-β.1, -γ.1, and δ1. Biochemistry 33:3032–3037
120. Hanakam F, Gerisch G, Lotz S, Alt T, Seelig A (1996) Binding of hisactophilin I and II to lipid membranes is controlled by a pH-dependent myristoyl−histidine switch. Biochemistry 35:11036–11044
121. Fischer H, Gottschlich R, Seelig A (1998) Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol 165:201–211
122. Lennarnas H, Abrahamsson B (2005) The use of biopharmaceutical classification of drugs in drug discover and development: current status and future extensions. J Pharm Pharmacol 57:273–285
123. Smart B (2001) Fluorine substituent effects (on bioactivity). J Fluor Chem 109:3–11
124. Jacobs RT, Bernstein PR, Cronk LA, Vacek EP, Newcomb LF, Aharony D, Buckner CK, Kusner EJ (1994) Synthesis, structure-activity relationships, and pharmacological evaluation of a series of fluorinated 3-benzyl-5-indolecarboxamides: identification of 4-[[5-[((2R)-2-methyl- 4,4,4-trifluorobutyl)carbamoyl]-1-methylindol-3-yl]methyl]-3methoxy-N-[(2-methylphenyl)sulfonyl]benzamide, a potent, orally active antagonist of leukotrienes D4 and E4. J Med Chem 37:1282–1297
125. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR, (1999) MDCK (Madin–Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:23–33
126. Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PY (2001) Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro- 2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 44:566–578
127. Shimizu H, Yamasaki T, Yoneda Y, Muro F, Hamada T, Yasukochi T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S (2011) Discovery of imidazo[1,2- b ]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models. Bioorg Med Chem Lett 21:4550–4555 and refs therein 128.
128. PAMPA: Parallel Artificial Membrane Permeability Assay is a method which determines the permeability of substances from a donor compartment, through a lipid-infused artifi cial membrane into an acceptor compartment. PAMPA models regularly exhibit a high degree of correlation with permeation across a variety of barriers including Caco-2 cultures, the GI tract, blood-brain barriers and skin
129. Carosati E, Sciabola S, Cruciani G (2004) Hydrogen-bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. J Med Chem 47:5114–5125
130. Pfleiderer T, Waldner I, Bertagnolli H, Tödheide K, Fischer HE (2000) The structure of liquid and supercritical deuterium fluoride from neutron scattering and using high-pressure techniques. J Chem Phys 113:3690–3696
131. Barbarich TJ, Rithner CD, Miller SM, Anderson OP, Strauss SH (1999) Significant inter- and intra-molecular O-H⋯F-C hydrogen-bonding. J Am Chem Soc 121:4280–4281
132. Murray-Rust P, Stallings WC, Monti CT, Preston RK, Glusker JP (1983) Intermolecular interactions of the C-F Bond: the crystallographic environment of fluorinated carboxylic acids and related structures. J Am Chem Soc 105:3206–3214
133. Scerba MT, Leavitt CM, Diener ME, DeBlase AF, Guasco TL, Siegler MA, Bair N, Johnson MA, Lectka T (2011) NH + −F hydrogen-bonding in a fluorinated “Proton Sponge” derivative: integration of solution, solid-state, gas-phase, and computational studies. J Org Chem 76:7975–7984
134. Prakash GKS, Wang F, Rahm M, Shen J, Ni C, Haiges R, Olah GA (2011) On the nature of C-H⋯F-C interactions in hindered CF3 -C(sp3) bond rotations. Angew Chem Int Ed 50:11761–11764
135. Chopra D (2012) Is organic fluorine really “not” polarizable? Cryst Growth Des 12:541–546
136. Dunitz JD (2004) Organic fluorine: odd man out. ChemBioChem 5:614–621
137. Cormanich RA, Freitas MP, Tormena CF, Rittner R (2012) The FHO intramolecular hydrogen bond forming five-membered rings hardly appear in monocyclic organofluorine compounds. RSC Adv 2:4169–4174
138. Dunitz JD, Taylor R (1997) Organic fluorine hardly ever accepts hydrogen bonds. Chem Eur J 3:89–98
139. Fonseca TAO, Ramalho TC, Freitas MP (2012) F⋯HO intramolecular hydrogen bond as the main transmission mechanism for 1h J F, H(O) coupling constant in 2′-fluorofl avonol. Magn Reson Chem 50:551–556
140. Cormanich RA, Moreira MA, Freitas MP, Ramalho TC, Anconi CPA, Rittner R, Contreras RH, Tormena CF (2011) 1hJF, H coupling in 2-fluorophenol revisited: is intramolecular hydrogen bond responsible for this long-range coupling? Magn Reson Chem 49:763–767
141. Nolting DN, Nickels ML, Huo N, Pham W (2012) Molecular imaging probe development: a chemistry perspective. Am J Nucl Med Mol Imaging 2:273–306
142. Le Bars D (2006) Fluorine-18 and medical imaging: radiopharmaceuticals for positron emission tomography. J Fluor Chem 127:1488–1493
143. Miller PW, Long NJ, Vilar R, Gee AD (2008) Synthesis of 11C, 18F, 15O and 13N radiolabels for positron emission tomography. Angew Chem Int Ed 47:8998–9033
144. Ametamey SM, Honer M, Schubiger PA (2008) Molecular imaging with PET. Chem Rev 108:1501–1516
145. Pauwels EKJ, van der Klaauw AA, Corporaal T, Stokkel MPM (2002) Fluorine-18-radiolabeled pharmaceuticals for imaging with positron emission tomography, excluding [18F]-fluorodeoxyglucose. Drugs Future 27:655–667
146. Daniels S, Farah M, Tohid S, Velanguparackel W, Westwel AD (2010) The role and future potential of fluorinated biomarkers in positron emission tomography. Expert Opin Drug Discov 5:291–304
147. Sharma S, Rodriguez AL, Conn PJ, Lindsley CW (2008) Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg Med Chem Lett 18:4098–4101
148. Sams AG, Mikkelsen AK, Brodbeck RMG, Pu X, Ritzén A (2011) Efficacy switching SAR of mGluR5 allosteric modulators: highly potent positive and negative modulators from one chemotype. Bioorg Med Chem Lett 21:3407–3410
149. Packiarajan M, Mazza Ferreira CG, Hong S-P, White AD, Chandrasena G, Pu X, Brodbeck RM, Robichaud AJ (2012) N-Aryl pyrrolidinonyl oxadiazoles as potent mGluR5 positive allosteric modulators. Bioorg Med Chem Lett 22:5658–5662
150. Packiarajan M, Mazza Ferreira CG, Hong S-P, White AD, Chandrasena G, Pu X, Brodbeck RM, Robichaud AJ (2012) Azetidinyl oxadiazoles as potent mGluR5 positive allosteric modulators. Bioorg Med Chem Lett 22:6469–6474
151. Schirrmacher R, Wängler C, Schirrmacher E (2007) Recent developments and trends in 18 F-radiochemistry: syntheses and applications. Mini Rev Org Chem 4:317–329
152. Cai L, Lu S, Pike VW (2008) Chemistry with [18F]-fluoride ion. Eur J Org Chem 2853–2873
153. Littich R, Scott PJH (2012) Novel strategies for fluorine-18 radiochemistry. Angew Chem Int Ed 51:1106–1109
154. Hollingworth C, Gouverneur V (2012) Transition metal catalysis and nucleophilic fluorination. Chem Commun 48:2929–2942
155. Prakash GKS, Chacko S (2008) Novel nucleophilic and electrophilic fluoroalkylation methods. Curr Opin Drug Discov Dev 11:793–802
156. Shimizu M, Hiyama T (2004) Modern synthetic methods for fluorine-substituted target molecules. Angew Chem Int Ed 44:214–231
157. Kirk KL (2008) Fluorination in medicinal chemistry: methods, strategies, and recent developments. Org Proc Res Dev 12:305–321
158. Furuya T, Kuttruff CA, Ritter T (2008) Carbon-fluorine bond formation. Curr Opin Drug Discov Dev 11:803–819
159. Pauwels EKJ (2001) 18F-Labeled fluorodeoxyglucose for PET imaging: the working mechanism and its clinical implication. Drugs Future 26:659–668
160. Gatley SJ, Volkow ND, Fowler JS, Ding Y-S, Logan J, Wang G-J, Gifford AN (2003) Positron emission tomography and its use to image the occupancy of drug binding sites. Drug Dev Res 59:194–207
161. Berridge MS, Heald DL, Lee Z (2003) Imaging studies of biodistribution and kinetics in drug development. Drug Dev Res 59:208–226
162. Hicks JW, Van Brocklin HF, Wilson AA, Houle S, Vasdev N (2010) Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT. Molecules 15:8260–8278
163. Badgaiyan RD (2011) Neurotransmitter imaging: basic concepts and future perspectives. Curr Med Imaging Rev 7:98–103
164. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY (2008) 6-L- 18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 49:573–586
165. Minn H, Kauhanen S, Seppanen M, Nuutila P (2009) 18F-FDOPA: a multiple-target molecule. J Nucl Med 50:1915–1918
166. Garnett ES, Firnau G, Nahmias C (1983) Dopamine visualized in the basal ganglia of living man. Nature 305:137–138
167. DeJesus OT (2003) Positron-labeled DOPA analogs to image dopamine terminals. Drug Dev Res 59:249–260
168. Goodman MM, Kilts CD, Keil R, Shi B, Martarello L, Xing D, Votaw J, Ely TD, Lambert P, Owens MJ, Camp VM, Malveaux E, Hoffman JM (2000) 18F-Labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol 27:1–12
169. Davis MR, Votaw JR, Bremner JD, Byas-Smith MG, Faber TL, Voll RJ, Hoffman JM, Grafton ST, Kilts CD, Goodman MM (2003) Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med 44:855–861
170. Elsinga PH, Hatano K, Ishiwata K (2006) PET tracers for imaging of the dopaminergic system. Curr Med Chem 13:2139–2153
171. Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE (2006) WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacol 188:244–251
172. Lang L, Jagoda E, Schmall B, Vuong B-K, Adams HR, Nelson DL, Carson RE, Eckelman WC (1999) Development of fluorine-18-labeled 5-HT 1A antagonists. J Med Chem 42:1576–1586
173. Lemaire C, Cantineau R, Marcel Guillaume M, Plenevaux A, Christiaens L (1991) Fluorine-18- altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med 32:2266–2272
174. Herth MM, Kramer V, Piel M, Palner M, Riss PJ, Knudsen GM, Roesch F (2009) Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT 2A receptor imaging with PET. Bioorg Med Chem 17:2989–3002
175. Gao Y, Kuwabara H, Spivak CE, Xiao Y, Kellar K, Ravert HT, Kumar A, Alexander M, Hilton J, Wong DF, Dannals RF, Horti AG (2008) Discovery of (−)-7-methyl-2-exo-[3′-(6-[ 18 F] fluoropyridin-2-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (α4β2-nAChR) with optimal positron emission tomography imaging properties. J Med Chem 51:4751–4764
176. Yang L, Rieves D, Ganley C (2012) Brain amyloid imaging – FDA approval of fl orbetapir F18 injection. New Engl J Med 367:885–887
177. Garber K (2012) First FDA-approved beta-amyloid diagnostic hits the market. Nat Biotechnol 30:575
178. Kung HF, Choi SR, Qu W, Zhang W, Skovronsky D (2010) 18F Stilbenes and styrylpyridines for PET imaging of Aβ plaques in Alzheimer’s disease: a miniperspective. J Med Chem 53:933–941
179. Kung HF, Lee C-W, Zhuang ZP, Kung MP, Hou C, Plossl K (2001) Novel stilbenes as probes for amyloid plaques. J Am Chem Soc 123:12740–12741
180. Wang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF (2005) F-18 stilbenes as PET imaging agents for detecting β-amyloid plaques in the brain. J Med Chem 48:5980–5988
181. Qu W, Kung MP, Hou C, Benedum TE, Kung HF (2007) Novel styrylpyridines as probes for SPECT imaging of amyloid plaques. J Med Chem 50:2157–2165
182. Zhang W, Oyas S, Kung MP, Hou C, Maier DL, Kung HF (2005) F-18F PEG stilbenes as PET imaging agents targeting Aβ aggregates in the brain. Nucl Med Biol 32:799–809
183. Zhang W, Kung MP, Oya S, Hou C, Kung HF (2007) 18F-labeled styrylpyridines as PET agents for amyloid plaque imaging. Nucl Med Biol 34:89–97
184. Stephenson KA, Chandra R, Zhuang Z-P, Hou C, Oya S, Kung M-P, Kung HF (2007) Fluoropegylated (FPEG): imaging agents targeting Aβ aggregates. Bioconjug Chem 18:238–246
185. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, Benedum TE, Kilbourn MR, Skovronsky D, Kung HF (2009) Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med 50:1887–1894
186. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brašić JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ (2010) In vivo imaging of amyloid deposition in Alzheimer’s disease using the radioligand 18F-AV-45 (florbetapir F18). J Nucl Med 51:913–920
187. Clark CM, Schneider JA, Bedell BJ, Beach TC, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman PEM, Zehntner SP, Skovronsky DM (2011) Use of florbetapir-PET for imaging β-amyloid pathology. J Am Med Assoc 305:275–283
188. Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A, Berndt M, McLean CA, Krause S, Rowe CC, Masters CL, Dinkelborg L, Dyrks T, Cappai R (2012) In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. Nucl Med Biol 39:1042–1048
189. Ashford JW, Rosen A, Adamson M, Bayley P, Sabri O, Furst A, Black SE, Weiner M, Barthel H, Sabri O (2011) Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET. J Alzheimer’s Dis 26(Suppl 3):117–121
190. Barthel H, Gertz H-J, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O (2011) Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 10:424–435
191. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O’Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters C, Rowe CC L (2011) Amyloid imaging with 18 F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 52:1210–1217
192. Nelissen N, van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, Bormans G, Brooks DJ, Vandenberghe R (2009) Phase 1 study of the Pittsburgh compound B derivative 18 F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 50:1251–1259
193. Wong DF, Moghekar Abhay R, Rigamonti D, Brasic JR, Rousset O, Willis W, Buckley C, Smith A, Gok B, Sherwin P, Grachev ID (2013) An in vivo evaluation of cerebral cortical amyloid with 18 F-flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients. Mol Imaging Biol 15: 230–237
194. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68:319–329
195. Cselenyi Z, Joenhagen ME, Forsberg A, Halldin C, Julin P, Schou M, Johnstroem P, Varnaes K, Svensson S, Farde L (2012) Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med 53:415–424
196. Jureus A, Swahn B-M, Sandell J, Sandell J, Jeppsson F, Johnson AE, Johnstroem P, Neelissen JAM, Sunnemark D, Farde L, Svensson SPS (2010) Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand. J Neurochem 114:784–794
197. Li Z, Conti PS (2010) Radiopharmaceutical chemistry for positron emission tomography. Adv Drug Deliv Rev 62:1031–1051
198. Riss PJ, Ferrari V, Brichard L, Burke P, Smith R, Aigbirhio FI (2012) Direct, nucleophilic radiosynthesis of [18F]-trifluoroalkyl tosylates: improved labelling procedures. Org Biomol Chem 10:6980–6986
199. Moon BS, Kil HS, Park JH, Kim JS, Park J, Chi DY, Lee BC, Kim SE (2011) Facile aromatic radiofluorination of [18F]-fl umazenil from diaryliodonium slats with evaluation of their stability and selectivity. Org Biomol Chem 9:8346–8355
200. Lee E, Kamlet AS, Powers DC, Neumann CN, Boursalian GB, Furuya T, Choi DC, Hooker JM, Ritter T (2011) A fluoride-derived electrophilic late-stage fluorination reagent for PET imaging. Science 334:639–642
201. Liu W, Huang X, Cheng M-J, Nielsen RJ, Goddard WA III, Groves JT (2012) Oxidative aliphatic C-H fluorination with fluoride ion catalyzed by a manganese porphyrin. Science 337:1322–1325